Press Releases

2024.11.21

I-Mab to Participate at the Piper Sandler Healthcare Conference

The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024 ROCKVILLE, MD, November 21, 2024 – I-Mab (NASDAQ: IMAB, the “Company”), a U.S.-based global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Piper Sandler 36th […]

2024.11.14

I-Mab Reports Third Quarter 2024 Results

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025 Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024 Estimated cash runway into 2027, based on $184.4 million in cash and […]

2024.11.06

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

ROCKVILLE, MD, November 6, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu, PhD, MBA has been appointed as the Company’s permanent Chief Executive Officer (“CEO”) effective November 1, 2024. Dr. Fu […]

View all Press Releases

Partner News

View all Partner News

Media Reports

View all Media Reports